Fibromyalgia and the endocannabinoid system

Authors: John M. McPartland Published in Science Direct November 2009 Introduction Fibromyalgia has been characterized as an ‘endocanna- binoid (eCB) deficiency syndrome’, along with other refractory maladies such as irritable bowel syndrome, migraine, premenstrual syndrome and other pain- processing disorders (Russo 2004). This syndrome may arise from diminished receptor expression, inadequate ligand biosynthesis or gain-of-function…

Cannflavins – From plant to patient: A scoping review

Authors: Simon Erridge, Nagina Mangal, Oliver Salazar, Barbara Pacchetti, Mikael H.Sodergren Published in Fitoterapia October 2020 Abstract Introduction Cannflavins are a group of prenylflavonoids derived from Cannabis sativa L.. Cannflavin A (CFL-A), B (CFL-B) and C (CFL-C) have been heralded for their anti-inflammatory properties in pre-clinical evaluations. This scoping review aims to synthesise the evidence…

Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK

Authors: Young Sun Hwang, Youn-Jung Kim, Mi Ok Kim, Mingyeong Kang, Sae Woong Oh, Youn Hwa Nho, See-Hyoung Park, Jongsung Lee Published in Science Direct August 2017 Abstract Melanogenesis plays a critical role in the protection of skin against external stresses such as ultraviolet irradiation and oxidative stressors. This study was aimed to investigate the…

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients

Authors: Jeffrey Y. Hergenrather, Joshua Aviram, Yelena Vysotski, Salvatore Campisi-Pinto, Gil M. Lewitus, David Meiri Published in Rambam Maimonides Medical Journal January 2020 Abstract Objective The aim of this cross-sectional questionnaire-based study was to identify associations between the doses of cannabinoids and terpenes administered, and symptoms of attention deficit hyperactivity disorder (ADHD). Methods: Participants were adult patients…

Cannabis Nurses Answer Common Patient Inquiries

The SCC hears from three seasoned Cannabis Nurses as they share their insight on modes of administration, patient access, and adversity to the cannabis “high”.

Terpenes/Terpenoids in Cannabis: Are They Important?

Authors: Hanuš LO. · Hod Y. Published in Karger  August 2020 Abstract Cannabis sativa plant has not only cannabinoids as crucial compounds but also the other compounds that play important role as synergistic and/or entourage compound. Cannabis/hemp plant materials and essential oils were analyzed with the help of gas chromatography/mass spectrometry detector for the content of…

Cannabis and Cannabidiol (CBD) for the Treatment of Fibromyalgia

Authors: Amnon A.Berger MD, PhD, Joseph Keefe BM, Ariel Winnick MA, Elasaf Gilbert BS, Jonathan P.Eskander MD, MBA, Cyrus Yazdi MD, Alan D.Kaye MD, PhD, Omar Viswanath MD, Ivan Urits MD Published in Science Direct  August 2020 Abstract Background Fibromyalgia is a complex disease process that is as prevalent as it is poorly understood. Research into…

Cannabis Therapeutics and the Future of Neurology

Author: Ethan B. Russo Published in: Frontiers in Integrative Neuroscience  October 2018 Abstract Introduction: Cannabis burst across the Western medicine horizon after its introduction by William O’Shaughnessy in 1838 (O’Shaughnessy, 1838–1840; Russo, 2017b), who described remarkable successes in treating epilepsy, rheumatic pains, and even universally fatal tetanus with the “new” drug. Cannabis, or “Indian hemp,” was…

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

Author: Alex Capano, Richard Weaver & Elisa Burkman Published in Postgraduate Medicine   November 2019 Abstract Context: Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy…

A Comprehensive Patient and Public Involvement Program Evaluating Perception of Cannabis-Derived Medicinal Products in the Treatment of Acute Postoperative Pain, Nausea, and Vomiting Using a Qualitative Thematic Framework

Author: Simon Erridge, Marie Miller, Tamara Gall, Antonio Costanzo, Barbara Pacchetti, and Mikael H. Sodergren Published in Mary Ann Liebert, Inc Publishers  February 2020 Abstract Introduction: Cannabis-derived medicinal products (CDMPs) have antiemetic properties and in combination with opioids have synergistic analgesic effects in part signaling through the delta and kappa opioid receptors. The objective of this patient…

Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors

Authors: Belén Palomares, Martín Garrido‐Rodriguez, Claudia Gonzalo‐Consuegra, María Gómez‐Cañas, Suwipa Saen‐oon, Robert Soliva, Juan A. Collado, Javier Fernández‐Ruiz, Gaetano Morello, Marco A. Calzado, Giovanni Appendino, Eduardo Muñoz Published in British Journal of Pharmacology  June 2020 Abstract Background and Purpose: Δ9‐Tetrahydrocannabinolic acid (Δ9‐THCA‐A), the precursor of Δ9‐THC, is a non‐psychotropic phytocannabinoid that shows PPARγ agonist activity. Here,…

The practical knowledge, experience and beliefs of US emergency medicine physicians regarding medical Cannabis: A national survey

Author: Kevin M Takakuwa, Frances S Shofer, Raquel M Schears Published in The American Journal of Emergency Medicine  January 2020 Introduction Medical cannabis is legal in 33 US states [ 1 ] but remains federally illegal. The majority of legal states require physicians to provide cannabis recommendations in order for patients to have access to it….